Pregnancy complications, such as preterm birth, preeclampsia, and gestational diabetes, affect 45 million women globally each year — triple the rate of cancer incidence. Yet, little is known about the underlying molecular basis of these complications and today there is no reliable way to identify if a mother is at risk and to take early action.
Mirvie’s mission is to redefine pregnancy health with the first early detection RNA test to address this critical unmet need. Mirvie offers a personalized window into pregnancy by using state-of-the-art machine learning and liquid biopsy technology to analyze tens of thousands of molecular messages from the mother, baby and placenta – all from a simple blood sample. Mirvie was founded in 2018 by a team of scientific and business pioneers that have an extensive track record innovating, developing and commercializing non-invasive and liquid biopsy tests used by millions of individuals today. Mirvie has raised over $30M in early-stage financing from top-tier investors, including Khosla Ventures and Mayfield Fund. Mirvie is based in South San Francisco, California.